

Outperform → | Target Price : € 16.0

Price (05/11/2025) : € 7.80 | Upside : 105%

Revision


EPS

12/25e 12/26e

40.6%

A solid business development in 9M 2025

Publication date: 06/11/2025 08:45 Writing date: 06/11/2025 08:17



Sources: ODDO BHF Securities, SIX

Share data		
TPG GY TPGG.DE		
Market Cap (€m)		159
Enterprise value (€m)		287
Extrema 12 months (€)	7.20 _	12.90
Free Float (%)		20.1

Performance (%)	1m	3m	12m
Absolute	-13.5	-7.4	2.4
Perf. rel. Country Index	-13.5	-14.2	-9.5
Perf. rel. SDAX	-6.7	-1.1	-14.8

P&L	12/25e	12/26e	12/27e
Sales (€m)	717	938	981
EBITDA (€m)	79.7	76.3	80.3
Current EBIT (€m)	69.8	66.3	70.3
Attr. net profit (€m)	47.4	38.7	41.5
Adjusted EPS (€)	2.32	1.90	2.03
Dividend (€)	0.00	0.00	0.00
P/E (x)	3.4	4.1	3.8
P/B (x)	0.7	0.6	0.5
Dividend Yield (%)	0.0	0.0	0.0
FCF yield (%)	14.0	26.6	22.9
EV/Sales (x)	0.40	0.29	0.27
EV/EBITDA (x)	3.6	3.6	3.3
EV/Current EBIT (x)	4.1	4.1	3.8
Gearing (%)	55	44	35
Net Debt/EBITDA (x)	1.6	1.5	1.3

14/11/2025

Q3 Results

Sales and profitability up y-o-y, but slightly below our estimates

During the first nine months of 2025, TPG generated net sales of € 531.6m (+43.2% y-o-y, +1.8% vs ODDO BHFe) and an adj. EBITDA (mainly due to the comprehensive cost and efficiency program implemented since 2023) of € 45.8m (+86.2% y-o-y, -4.2% vs. ODDO BHFe). As a result, the adj. EBITDA margin rose by 200bp to 8.6% (-60bp vs ODDO BHFe). Growth in revenue (of which organic growth was +26.3% vs +18.4% in 9M 2024) was driven by the increase in the number of connected partners to 15,931 (+22.7% y-o-y) and the expansion of platform and software solutions to 28 sectors (vs. 23 sectors a year ago). Eleven acquisitions were completed during 9M 2025, of which eight were already consolidated in the reporting period. Similarly, the number of active customers increased by 48.9% to 6.7m and the order volume by 49.0% to 7.6m.

9M 2025 resul	lts vs estimate	es			
€m	9M 2025	9M 2024	у-о-у	ODDO BHFe	Δ
GMV	902.1	608.4	+48.4%	975.0	-7.5%
Net Sales	531.6	371.2	+43.2%	522.2	+1.8%
Adj. EBITDA	45.8	24.6	+86.2%	47.8	-4.2%
Margin	8.6%	6.6%	+200bp	9.2%	-60bp

Sources: ODDO BHF Securities, company

2025 forecast confirmed

As expected, TPG confirmed its 2025 outlook for GMV of at least € 1.3bn (ODDO BHFe € 1.29bn), net sales of between € 715m and € 735m (ODDO BHFe 716.7m, consensus € 724.9m) and adj. EBITDA of between € 54m and € 58m (ODDO BHFe € 58.7m).

Target price and rating maintained

We have 1) updated our 2026e to 2027e numbers to reflect TPG's 2026 mid-term guidance and 2) confirm our Outperform rating and target price of € 16.

Klaus Breitenbach (Analyst) +49 (0) 69 718 1011 klaus.breitenbach@oddo-bhf.com

Page 1/5

 $ODDO\ BHFSCA\ or\ its subsidiaries\ and\ the\ issuer\ have\ agreed\ on\ the\ provision\ by\ the\ first\ to\ the\ second\ of\ a\ service\ for\ the\ production\ and\ dissemination\ of\ the\ investment\ recommendation\ for\ said\ issuer\ have\ agreed\ on\ the\ provision\ by\ the\ first\ to\ the\ second\ of\ a\ service\ for\ the\ production\ and\ dissemination\ of\ the\ investment\ recommendation\ for\ said\ issuer\ have\ agreed\ on\ the\ production\ and\ dissemination\ of\ the\ investment\ recommendation\ for\ said\ issuer\ have\ agreed\ on\ the\ production\ and\ dissemination\ of\ the\ investment\ recommendation\ for\ said\ issuer\ have\ agreed\ on\ the\ production\ and\ dissemination\ of\ the\ investment\ recommendation\ for\ said\ issuer\ have\ agreed\ on\ the\ production\ and\ dissemination\ of\ the\ investment\ recommendation\ for\ said\ issuer\ have\ agreed\ on\ the\ production\ and\ dissemination\ of\ the\ investment\ recommendation\ for\ said\ investment\ production\ and\ dissemination\ of\ the\ investment\ production\ and\ dissemination\ of\ the\ investment\ production\ and\ dissemination\ of\ the\ investment\ production\ and\ on\ the\ production\ and\ production\ and\ on\ the\ investment\ production\ and\ production\ and\ and\ production\ and\ production\ and\ production\ and\ and\ production\ and\ production\ and\ and\ production\ and$ ODDO BHF SCA and/or one of its subsidiaries could be in a conflict of interest situation with one or several of the issuers mentioned in this publication. Please refer to the conflict of interests section at the

Thursday, November 6, 2025



Migner M	The Platform Group	Outperform			Price 7.80)€	
Spinor PS		Upside 105.13%			TP 16.0)€	
Manual Property 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,							12/27e
Section 1.00							2.03 2.03
Process 1988 1988 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989 1989			-				7.2%
Babbase granger winder geling 1406 1407 1408 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 1409 140	·						0.00
Nember of districts of part in the part of par							1.79 14.94
NUMBER 1972 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978 1978							20.42
Description of the content of the	Number of diluted shares (m)		17.27		20.42		20.42
Deminstration 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988			12/23			12/26e	12/27e
Fleenergerschild							
Research cented						7.80	7.80
Manufact devided 1.1 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	Capitalization						159
Handlandsoatelyravaled 15							108
Prevision 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0							3.2 3.5
P.							0.0
Section 10	Enterprise Value			269	287	274	267
Name							3.8
Fryside 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906 1906							3.6 0.0%
PR INCL ON/YOL PR CASC ON/YOL PR CASC ON YOL PR C							22.9%
Published Flat Publ				1.28		0.61	0.52
March Marc							0.52
Producted reserver price 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1988 1							0.27 3.3
PROFIT ANDIOSISM 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 1278 12							3.8
Sales 462 252 717 988 Deprocation 468 459 100 100 Deprocation 178 468 179 1100 Published BUT 189 468 179 1100 Not francial income 464 488 179 100 Not francial income 464 488 179 100 Not francial income 464 488 170 100 Not income depath sectorities (intertus) 100 100 100 100 Not income depath sectorities (intertus) 10 16 10 10 Not income depath sectorities (intertus) 118 312 474 383 Attributable ent profit 318 312 474 383 Attributable ent profit 318 312 474 383 Deck States 37 18 120 16 112 Deck States 37 12 176 14 112 12 12			-10/00	40/01	10/05	10.00	40.00
BITDA							12/27e 981
Depreciations							80
Pablished EIIT			-7.8			-10.0	-10.0
Net brancal lincome .6.4 .9.4 .9.6 .9.5 Corporate Ias .0.4 .0.8 .11.8 .11.0 Nel income of equity-accounted companies .0.0 .0.0 .0.0 .0.0 Porticibles of discontinued activities (infert tad) .0.0 .0.0 .0.0 .0.0 Porticibles of sincontinued activities (infert tad) .0.0 .0.0 .0.0 .0.0 Affinizabile net profit .0.0 .0.0 .0.0 .0.0 .0.0 Affinizabile net profit .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 Affinizabile net profit .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0 .0.0<							70
Corporate Tax O.04 0.08 1.18 1.70 Profit income of equily-accounted companies 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 <							70 -9.6
Pontifundes of discontinued activities (after tax) Do Calib Color Co							-18.2
Minority interests 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1							0.0
Arributable net profit 318 312 474 88.7 Malquisted altributable net profit 318 312 474 88.7 Malquisted altributable net profit 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 1272 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>0.0 -1.0</td></th<>							0.0 -1.0
Aginted stributable net profit 31.8 31.2 37.4 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37							41.5
Cooker intangible seasts 44.8 47.5 47.5 47.5 Tangible freed assets 46.0 89.2 19.0 17.0 7.7 Tingible freed assets 37.0 18.0 14.0 11.2 17.0 18.0 14.0 11.2 17.0 18.0 14.0 11.0 18.0 17.0 18.0 11.0 12.0 20.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0	Adjusted attributable net profit		31.8	31.2	47.4	38.7	41.5
Other Instalplie sacets 46,0 89,2 91,0 92,7 MCR 38,0 73,6 76,0 71,8 Financial sacets 11,7 22,0 146 169 Ordinary shareholders equity 80,5 132 229 260 Ordinary shareholders equity 81,6 133 222 260 Ordinary shareholders equity 81,6 133 222 260 Ordinary shareholders equity 81,6 133 222 260 Non-current provisions 170 11,6 133 242 263 Non-current provisions 170 1,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6 14,6							12/27e 47.5
WCR 38.0 73.6 76.0 71.8 Financial sests 11.7 20.0 14.6 15.9 Ordinary shareholders equity 80.5 132 22.9 20.0 Minority interests 11.1 32.2 32.2 32.3 Shareholders equity 17.0 14.6 14.6 14.6 14.6 Net debt 17.0 14.6 14.6 14.6 14.6 14.6 Net debt 46.8 55.6 17.7 76.3 12.2 12/24 12/25 12/26 1 CASSIFLOW STATEMENT (cm) 38.0 35.6 2.4 4.2 1 1.1 3.2 12.2 12/24 12.2 12/24 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 1							94.5
Financial sissets							7.8
Ordinary shareholders equity 80.5 13.2 22.9 25.0 Minority interests 1.1 3.2 3.2 2.2 Shareholders equity 41.6 13.5 23.2 2.63 Non-current provisions 17.0 14.6 14.6 14.6 Net debt 68.5 101 12.8 11.5 CASHELOWSTATEMENT (cm) 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2 12/2							71.6
Minority interests 11 32 32 32 32 32 32 32							209 305
Non-current provisions 17.0 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.6 14.							3.2
Net debt							308
CASHENOSATEMENT (Fm) 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28 12/28							14.6 108
Change in WCR -38.6 -35.6 -2.4 4.2 Interests & taxes 6.6 13.7 2.1 7.4 Others 88.7 24.3 -44.6 -22.4 Operating Cash flow 10.1 5.7 30.5 50.7 CAPEX -21.0 -61.1 82.7 30.5 50.7 Free cash-flow 83.0 49.8 22.3 42.4 -61.0 10.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0							12/27e
Internst & taxes 6.6 13.7 7.1 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.	EBITDA						80.3
Others 88.7 24.3 44.6 -22.4 CAPEX 104.1 5.79 3.05 5.07 CAPEX 21.0 8.81 6.82 8.83 Free cash-flow 83.0 49.8 22.3 42.4 Acquisitions/disposals 58.8 48.4 55.0 0.0 Dividends 0.0 0.0 0.0 0.0 Other capital increase 0.0 0.1 15.5 -18.5 Change innet cash 25.3 2.1 12.5 -18.5 Converted Marcians 12.2 12.2 12.5 -18.5 Call Sagnowth 1.2 12.2 12.5 -18.5 Call Sagnowth 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.							0.3
Operating Cash flow 104.1 57.9 30.5 50.7 CAPEX 21.0 8.1 8.2 8.3 CRE cash-flow 83.0 44.8 22.3 42.4 Acquisitions / disposals 58.8 48.4 55.0 0.0 Dividends 0.0 0.0 0.0 0.0 Net again all ricrease 0.0 0.0 0.0 0.0 Others 4.0 0.0 0.0 0.0 Charge in et cash 25.3 32.1 27.8 13.3 Charge in et cash 12.3 12.2 12.5 18.5 Charge in et cash 12.3 12.2 12.5 18.5 Charge in et cash 12.3 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2							-8.6 -27.1
Free cash-flow 38.0 49.8 22.3 42.4 Acquisitions / disposals -58.8 -48.4 55.0 0.0 Net capital increase 0.0 0.0 0.0 0.0 Others 0.0 0.0 0.0 0.0 Charge in et cash 25.3 -20.1 12.5 13.3 CROWTH MARGINS PRODUCTIVITY 1.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.72 12.73 13.1 12.72 12.72							44.9
Acquisitions / disposals 58.8 48.4 -55.0 0.0 Dividends 0.0 0.0 0.0 0.0 Net capital increase 0.0 0.0 0.0 0.0 Change innet cash -25.3 -32.1 -27.8 1.8.5 CROWTH MARGINS PRODUCTIVITY 11/23 11/24 12/25 12/26 1 Sales growth - 2.1 3.66% 3.0% - Current EBIT growth - - - - - - Current EBIT growth - - 1.7.2% 52.5% 4.9% - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>-8.4</td></t<>							-8.4
Dividends 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0							36.5 0.0
Net capital increase 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0							0.0
Change in net cash 25.3 -32.1 -27.8 13.3 CROWIT MARGINSPRODUCTIVITY 12/23 12/24 12/25 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26							0.0
Sales growth 12/23 12/24 12/25 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26 12/26							-18.5
Sales growth - 21.4% 36.6% 30.7% Lf sale growth - - - - Current EBIT growth - 1.7.7% 52.5% -4.9% Crowth in adjusted EPS - - 1.7.2% 52.2% -18.4% Net margin 7.4% 5.9% 6.6% 4.1% EBITDA margin 10.8% 10.6% 11.1% 8.1% Current EBIT margin 9.0% 8.7% 9.7% 7.1% CAPEX/ Sales 4.9% 1.5% 1.1% 0.9% WCR / Sales 8.8% 14.0% 10.6% 7.7% VCR / Sales 4.9% 1.5% 1.1% 0.9% WCR / Sales 4.9% 1.5% 1.1% 1.2 1.2 1.2 1.2 1.2 1.2 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>7.4 12/27e</td>							7.4 12/27e
Current EBIT growth - 17.7% 52.5% -4.9% Crowth in adjusted EPS - -17.2% 52.2% -18.4% Net margin 7.4% 5.5% 6.6% 4.1% EBITDA margin 10.8% 10.6% 11.1% 8.1% CMPEX/ Sales 9,0% 8.7% -9.7% 7.1% CAPEX/ Sales 4.9% -1.5% 10.6% -7.7% Tax Rate 1.1% 2.2% 19.5% 30.0% -3.0% Normative tax rate 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0%							4.5%
Growth in adjusted EPS - 17.2% 52.2% - 18.4% Net margin 7.4% 5.9% 6.6% 4.1% EBITDA margin 10.8% 10.6% 11.1% 8.1% Current EBIT margin 9,0% 8.7% 9.7% 7.1% CAPEX/ Sales 4.9% -1.5% 9.7% 7.1% VCR / Sales 8.8% 11.0% 10.6% 7.7% Tax Rate 8.1% 2.2% 11.5% 30.0% 3.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% <t< td=""><td></td><td></td><td>-</td><td><u>-</u></td><td>-</td><td>-</td><td></td></t<>			-	<u>-</u>	-	-	
Net margin 7.4% 5.9% 6.6% 4.1% EBITDA margin 10.8% 10.6% 11.1% 8.1% Current EBIT margin 9.0% 8.7% 9.7% 7.1% CAPEX/ Sales 4.9% -1.5% -1.1% 0.9% WCR / Sales 8.8% 14.0% 10.6% 7.7% Tax Rate 1.1% 2.2% 19.5% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0%			-				6.0% 7.2%
EBITDA margin 10.8% 10.6% 11.1% 8.1% Curnet EBIT margin 9.0% 8.7% 9.7% 7.1% CAPEX/ Sales 4.9% 1.1% 9.0% 1.1% 9.0% WCR / Sales 8.8% 14.0% 11.0% 9.7% Tax Rate 1.1% 2.2% 19.5% 30.0% 1.2% Normative tax rate 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 40.1 41.1 40.1 41.1 40.1 41.1 40.1 41.1 40.1 41.1 40.1 41.1 40.1 41.1 41.1 40.0 40.0 41.1 40.0 41.1 40.0 40.0 40.0 40.0 <td></td> <td></td> <td>7.4%</td> <td></td> <td></td> <td></td> <td>4.2%</td>			7.4%				4.2%
CAPEX/Sales 4.9% -1.5% -1.1% -0.9% WCR / Sales 8.8% 14.0% 10.6% 7.7% TAX Rate -1.1% 2.2% 19.5% 30.0% 30.0% Normative tax rate 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 4.1 ROCE post-tax (normative tax rate) - 2.7 3.1 4.1 4.1 ROCE post-tax (GW (normative tax rate) - 21.9% 22.6% 15.9% 26.0% 15.9% 2.2 10.0% 15.9% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0%<	EBITDA margin		10.8%	10.6%	11.1%	8.1%	8.2%
WCR / Sales 8.8% 14.0% 10.6% 7.7% Tax Rate -1.1% 2.2% 19.5% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% <							7.2%
Tax Rate -1.1% 2.2% 19.5% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% 30.0% <							-0.9% 7.3%
Asset Turnover - 2.7 3.1 4.1 ROCE post-tax (normative tax rate) - 16,7% 21,4% 20,5% 2.5 ROCE post-tax excl GW (normative tax rate) - 21,9% 22,0% 26,0% 1.5 ROE - 29,3% 26,3% 15,9% 1.5 1.5 DEBT RATIOS 12/23 12/24 12/25 12/26 1 Gearing 84 74% 55% 44% NED to both Market Cap 1.6 0.81 0.72 Net debt/ FBITDA 147 1.81 1.61 1.51 1.51 EBITDA / net financial charges 7.3 5.9 8.3 7.9				2.2%	19.5%		30.0%
ROCE post-tax (normative tax rate) - 16.7% 21.4% 20.5% 2.7% 20.5% 2.7% 20.5% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%			30.0%				30.0%
ROCE post-tax excl GW (normative tax rate) - 21.9% 27.0% 26.0% 15.9% ROE - 29.3% 26.3% 15.9% 15.9% 15.9% 15.9% 12.2% 12.2% 12.2% 12.2% 12.2% 14.2% 12.2% 14.2% 12.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 14.2% 15.1% 14.2% 15.1% 14.2% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1% 15.1%			-				4.4 22.1%
ROE - 29.3% 26.3% 15.9% 15.9% 15.9% 15.9% 15.9% 15.9% 12.26 1 12.26 12.26 1 12.26 1 12.26 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1							28.2%
Gearing 84% 74% 55% 44% Net Debt / Market Cap 0.60 0.81 0.72 Net debt / EBITDA 1.47 1.81 1.61 1.51 EBITDA / net financial charges 7.3 5.9 8.3 7.9	ROE			29.3%	26.3%	15.9%	14.7%
Net Debt / Market Cap 0.60 0.81 0.72 Net debt / EBITDA 1.47 1.81 1.61 1.51 EBITDA / net financial charges 7.3 5.9 8.3 7.9							12/27e 35%
Net debt / EBITDA 1.47 1.81 1.61 1.51 EBITDA / net financial charges 7.3 5.9 8.3 7.9			0470				0.68
	Net debt / EBITDA			1.81	1.61	1.51	1.34
			7.3	5.9	8.3	7.9	8.4
Sources, Outpour Jecurities, 37X	Sources: ODDO BHF Securities, SIX						

Thursday, November 6, 2025



If yes, specify the name

Valuation method

Our target prices are established on a 12-month timeframe and we use three valuation methods to determine them. First, the discounting of available cash flows using the discounting parameters set by the Group and indicated on ODDO BHF' website. Second, the sum-of-the-parts method based on the most pertinent financial aggregate depending on the sector of activity. Third, we also use the peer comparison method which facilitates an evaluation of the company relative to similar businesses, either because they operate in identical sectors (and are therefore in competition with one another) or because they benefit from comparable financial dynamics. A mixture of these valuation methods may be used in specific instances to more accurately reflect the specific characteristics of each company covered, thereby fine-tuning its evaluation.

• Sensitivity of the result of the analysis/ risk classification:

The opinions expressed in the financial analysis are opinions as per a particular date, i.e. the date indicated in the financial analysis. The recommendation (cf. explanation of the recommendation systematic) can change owing to unforeseeable events which may, for instance, have repercussions on both the company and on the whole industry.

· Our stock market recommendations

Our stock market recommendations reflect the RELATIVE performance expected for each stock on a 12-month timeframe. Outperform: performance expected to exceed that of the benchmark index, sectoral (large caps) or other (small and mid caps). Neutral: performance expected to be comparable to that of the benchmark index, sectoral (large caps) or other (small and mid caps). Underperform: performance expected to fall short of that of the benchmark index, sectoral (large caps) or other (small and mid caps).

- The prices of the financial instruments used and mentioned in this document are the closing prices.
- All publications by ODDO BHF concerning the companies covered and mentioned in this document are available on the research site: www.securities.oddo-bhf.com/#disclaimer.

Recommendation and target price changes history over the last 12 months for the company analysed in this report				
Date	Reco	Price Target (EUR)	Price (EUR)	Analyst
02/05/25	Outperform	16.00	10.30	Klaus Breitenbach
27/11/24	Outperform	13.50	7.20	Klaus Breitenbach

In accordance with Article 20 of European Regulation No. 596/2014 (Market Abuse Regulation), a list of all recommendations on any financial instrument or issuer that have been disseminated over the past twelve months is available by clicking on the following link www.securities.oddo-bhf.com/#disclaimer.

Recommendation split				
		Outperform	Neutral	Underperform
Our whole coverage	(802)	50%	42%	9%
Liquidity providers coverage	(122)	46%	45%	9%
Research service coverage	(78)	58%	36%	6%
Investment banking services	(59)	63%	32%	5%

Risk of conflict of interest:

Investment banking and/or Distribution

	of the issuers concerned
Has ODDO BHF SCA or its affiliates managed or co-managed in the last 12 months a public offering of securities for the subject company/ies?	No
Has ODDO BHF SCA or its affiliates received compensation for other investment banking services from the subject company/ies in the last 12 months or expects to receive or intends to seek compensation for other investment banking services from the subject company/ies in the last 12 months?	No
Research contract between ODDO group & the issuer	If yes, specify the name of the issuers concerned
Have ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. and the subject company/ies agreed that ABN AMRO – ODDO BHF B.V. or one of its parent companies will produce and disseminate investment recommendations on the subject company/ies as a service to the the	The Platform Group

subject company/ies?

Liquidity provider agreement and market-making

If yes, specify the name of the issuers concerned

At the date of the distribution of this report does ODDO BHF SCA or its affiliates act as a market maker or has ODDO BHF SCA or its affiliates

No

signed a liquidity provider agreement with the subject company/ies?	
Significant equity stake	If yes, specify the name of the issuers concerned
Does ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. own 1% or more of any class of common equity securities of the subject company/ies?	No
One or more affiliates of ODDO BHF SCA other than ABN AMRO – ODDO BHF B.V. from time to time may own 1% or more of a class of common equity securities of the subject company/ies.	No
Does ODDO BHF SCA or its subsidiary ABN AMRO – ODDO BHF B.V. own a net long or short position of 0.5% or more of any class of common equity securities of the subject company/ies?	No
Does the subject company beneficially own 5% or more of any class of common equity of ODDO BHE SCA or its subsidiary ABN AMRO – ODDO	No

Disclosure to Company

BHF B.V.?

Thursday, November 6, 2025



Has the financial analysis been sent to the issuer for verification prior to publication?	No
Have any modifications been made to the conclusions of the analysis following its verification by the issuer?	No
Additional material conflicts	
Is ODDO BHF SCA or its affiliates aware of any additional material conflict of interest?	No
Personal conflicts of interest	
Do you buy or sell financial instruments from the issuer(s) concerned by this financial analysis?	No
Have those responsible for the drafting of the present document received remuneration directly linked to investment firm service transactions or any other kind of transaction they carry out or any trading commissions they or any legal person who is part of the same group receive?	No

 $Statement\ of\ conflict\ of\ interests\ of\ all\ companies\ mentioned\ in\ this\ document\ may\ be\ consulted\ on\ ODDO\ BHF:\ www.securities.oddo-bhf.com/\# disclaimer.$

Thursday, November 6, 2025

Disclaimer:



Disclaimers for Distribution by ODDO BHF SCA to Non-United States Investors:

This research publication is produced by the Investment Bank of ODDO BHF SCA ("ODDO BHF"), which is licensed by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the Autorité des Marchés Financiers ("AMF").

The research, when distributed outside of the U.S., is intended exclusively for non-U.S. customers of ODDO BHF and cannot be divulged to a third-party without prior written consent of ODDO BHF. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO BHF and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness, and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

Disclaimers for Distribution by ODDO BHF New York Corporation to United States Investors:

This Research Report is produced by the Investment Bank of ODDO BHF SCA ("ODDO BHF"). This research is distributed to U.S. investors exclusively by ODDO BHF New York Corporation ("ONY"), MEMBER: FINRA/SIPC, and is intended exclusively for U.S. customers of ONY and cannot be divulged to a third-party without prior written consent of ONY. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. This research has been prepared in accordance with regulatory provisions designed to promote the independence of investment research. "Chinese walls" (information barriers) have been implemented to avert the unauthorized dissemination of confidential information and to prevent and manage situations of conflict of interest. This research has been prepared in accordance with French regulatory provisions designed to promote the independence of investment research. The recommendation presented in this document is reviewed and updated at least quarterly following each Quarterly Report published by the issuer that is the subject of this Research Report.

At the time of publication of this document, ODDO BHF, and/or one of its subsidiaries may have a conflict of interest with the issuer(s) mentioned. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness, and it should not be relied upon as such. Past performances offer no guarantee as to future performances. All opinions expressed in the present document reflect the current context which is subject to change without notice. The views expressed in this Research Report accurately reflect the analyst's personal views about the subject securities and/or issuers and no part of his compensation was, is, or will be directly or indirectly related to the specific views contained in the Research Report. This Research Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice.

This Research Report is for institutional investors only. It may not contain information necessary for others to make investment decisions. Consult your financial adviser or an investment professional if you are not an institutional investor.

Disclosures Required by United States Laws and Regulations:

Rule 15a-6 Disclosure: Under Rule 15a-6(a)(3), any transactions conducted by ODDO BHF, and/or one of its subsidiaries with U.S. persons in the securities described in this foreign research must be effected through ONY. As a member of FINRA, ONY has reviewed this material for distribution to U.S. persons as required by FINRA Rules 2241(h) applicable to dissemination of research produced by its affiliate ODDO BHF.

FINRA Disclosures:

- Neither ONY, ODDO BHF beneficially owns 1% or more of any class of common equity securities of the subject company.
- The research analyst of ODDO BHF, at the time of publication of this research report, is not aware, nor does he or she know or have reason to know of any actual, material conflict of interest of himself or herself, ODDO BHF or ONY, except those mentioned in the paragraph entitled "Risks of Conflicts of Interest."
- ODDO BHF may receive or seek compensation for investment banking services in the next 3 months from the subject company of this Research Report, but ONY would not participate in those arrangements.
 Neither ONY or ODDO BHF has received compensation from the subject company in the past 12 months for providing investment banking services except those mentioned in
- the paragraph of "Risks of Conflict of Interest".

 Neither ONY or ODDO BHF, has managed or co-managed a public offering of securities for the subject company in the past 12 months except those mentioned in the paragraph
- of "Risk of Conflict of Interest".

 ONY does not make (and never has made) markets and, accordingly, was not making a market in the subject company's securities at the time that this research report was published.

Regulation AC:

ONY is exempt from the certification requirements of Regulation AC for its distribution to a U.S. person in the United States of this Research Report that is prepared by an ODDO BHF research analyst because ODDO BHF has no officers or persons performing similar functions or employees in common with ONY and ONY maintains and enforces written policies and procedures reasonably designed to prevent it, any controlling persons, officers or persons performing similar functions, and employees of ONY from influencing the activities of the third party research analyst and the content of research reports prepared by the third party research analyst.

Contact Information of firm distributing research to U.S. investors: ODDO BHF New York Corporation, MEMBER: FINRA/SIPC, is a wholly owned subsidiary of ODDO BHF SCA; Louis paul ROGER, President (louis-paul.roger@ny.oddo-bhf.com) 150 East 52nd Street New York, NY 10022 646-286-2137

Statement of conflict of interests of all companies mentioned in this document may be consulted on Oddo BHF research site.